<DOC>
	<DOCNO>NCT01181102</DOCNO>
	<brief_summary>The objective study assess efficacy safety DU-176b compare enoxaparin sodium prevention venous thromboembolism patient elective total knee arthroplasty .</brief_summary>
	<brief_title>A Phase 3 Study DU-176b , Prevention Venous Thromboembolism Patients After Total Knee Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Patients undergo unilateral total knee arthroplasty Subjects risk hemorrhage Subjects thromboembolic risk Subjects weigh less 40 kg Subjects pregnant suspect pregnancy , subject want become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>anticoagulant</keyword>
	<keyword>venus thromboembolism</keyword>
	<keyword>thrombosis</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>embolism thrombosis</keyword>
	<keyword>deep vein thrombosis</keyword>
	<keyword>DU-176b</keyword>
	<keyword>Edoxaban</keyword>
	<keyword>factor Xa</keyword>
	<keyword>total knee arthroplasty</keyword>
	<keyword>Enoxaparin sodium</keyword>
</DOC>